Countries where authors publish in Anti-Cancer Drugs
Since Specialization
Citations
This map shows the geographic impact of research published in Anti-Cancer Drugs. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by papers published in Anti-Cancer Drugs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anti-Cancer Drugs more than expected).
This network shows the impact of papers published in Anti-Cancer Drugs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers published in Anti-Cancer Drugs.
About Anti-Cancer Drugs
The 4.4k papers published in Anti-Cancer Drugs in the last decades have received a total of 85.1k indexed citations . Papers published in Anti-Cancer Drugs usually cover Oncology (2.1k papers), Cancer Research (658 papers), Toxicology (106 papers), Molecular Biology (2.0k papers) and Pulmonary and Respiratory Medicine (880 papers) specifically the topics of Cancer therapeutics and mechanisms (476 papers), Cancer Treatment and Pharmacology (474 papers), Colorectal Cancer Treatments and Studies (368 papers), Lung Cancer Treatments and Mutations (323 papers), Lung Cancer Research Studies (275 papers), HER2/EGFR in Cancer Research (176 papers), Drug Transport and Resistance Mechanisms (175 papers) and Cancer-related Molecular Pathways (171 papers). The most active scholars publishing in Anti-Cancer Drugs are Ruth Duncan, Jaap Verweij, Jos H. Beijnen, Howard L. McLeod, Daniel Morgensztern, S Hellman, S A Rosenberg, Vincent T. DeVita, Richard L. Momparler and Xiao-Chun Xu.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.